Comparative effectiveness of two intravenous immunoglobulin products in children with Kawasaki disease, a nationwide cohort study
Abstract Kawasaki Disease (KD) is the most common acquired pediatric heart disease in the developed world. Rapid infusion of high-dose intravenous immunoglobulin is the standard therapy. Different manufacturing processes of IVIG may influence their efficacy. This study aims to conduct a head to head...
Main Authors: | Ni-Chun Kuo, Ching-Heng Lin, Ming-Chih Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-10-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-45092-5 |
Similar Items
-
Effectiveness of two same-manufacturer intravenous immunoglobulin for Kawasaki disease
by: Kun-Lang Wu, et al.
Published: (2024-04-01) -
Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
by: Hun-Ju Yu, et al.
Published: (2021-03-01) -
Use of Corticosteroid in Children with Unresponsiveness to Intravenous Immunoglobulin in Kawasaki Disease
by: Abdolkarim Hamedi, et al.
Published: (2017-08-01) -
Pharmacogenomics of intravenous immunoglobulin response in Kawasaki disease
by: Sadeep Shrestha, et al.
Published: (2024-01-01) -
Hemolytic anemia associated with intravenous immunoglobulin in Kawasaki disease
by: Eun Jung Cheon, et al.
Published: (2024-01-01)